Kear Tamara M
Villanova University, Villanova, PA, USA.
Nephrol Nurs J. 2012 Mar-Apr;39(2):137-40.
Despite the use of epoetin alfa, over one-third of patients with end stage renal disease have persistent anemia. The nephrology literature cites various erythropoietin adjuvants that may have the potential to improve the efficiency of anemia management, and one option is ascorbic acid. This article reviews the published data on the effectiveness of intravenous ascorbic acid in increasing the hemoglobin levels of patients with hyporesponse to epoetin alfa, as well as adverse effects of the administration of intravenous ascorbic acid specifically in relation to hyperoxalemia.
尽管使用了促红细胞生成素α，但超过三分之一的终末期肾病患者仍存在持续性贫血。肾脏病学文献引用了各种可能有潜力提高贫血管理效率的促红细胞生成素佐剂，其中一种选择是抗坏血酸。本文综述了已发表的关于静脉注射抗坏血酸在提高对促红细胞生成素α反应低下患者血红蛋白水平方面有效性的数据，以及静脉注射抗坏血酸给药的不良反应，特别是与高草酸血症相关的不良反应。
